Fig. 8.
![Fig. 8. Reduced capacity of CML-DCs to migrate. / DCs were generated from healthy individuals (■ [A-B]; dotted lines [C-D]) and from CML patients (▪ [A-B]; solid lines [C-D]): patient 1 (A,C) and patient 6 (B,D). (A-B) Immature DCs were added to the 8 μm pore size filter in a transwell cell culture chamber. In the lower chamber MIP-1α was added. After 2, 5, and 24 hours, the DCs were counted in the lower chamber. (C-D) The expression of CCR1 on CML-DCs (solid lines) and DCs derived from healthy volunteers (dotted lines) was evaluated by staining with an anti-CCR1 mAb (thick lines) and isotype-matched mAb (thin lines). The results are representative of 11 experiments obtained with DCs derived from different patients as indicated in Table 1.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/101/9/10.1182_blood-2002-06-1841/4/h80934217008.jpeg?Expires=1724259501&Signature=QoWlijcEQgn1D4grdEh07BneUflqbFlkW36KMK04p2~54REPpFQAljtpV9ouwpDfLHtRKVOU1gV5PPNKdtdCgBm5kZVHDe9m~45sNjibqbKnz4CL7teCsXK1noOOyLHoGakL~gpfrxWy9Kibuzl~S8s6m7w1EYX7FROoSBcj9X2YzUbo68C2KDuUjq~BeKpA5YY8-nzU8tC~3yTUylZaHdZ8gCW0w8D-mJ-wdmWScxxX9Nm9IExLZtRWBag89FBQsExd1z99qFEDTnBPYBphzjylo6eMioZ8LXCY0mgrWDKUEmlbWaT~bX4TxkjHpjI1YHFgk7onwsg0KcEl1w5bEA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Reduced capacity of CML-DCs to migrate.
DCs were generated from healthy individuals (■ [A-B]; dotted lines [C-D]) and from CML patients (▪ [A-B]; solid lines [C-D]): patient 1 (A,C) and patient 6 (B,D). (A-B) Immature DCs were added to the 8 μm pore size filter in a transwell cell culture chamber. In the lower chamber MIP-1α was added. After 2, 5, and 24 hours, the DCs were counted in the lower chamber. (C-D) The expression of CCR1 on CML-DCs (solid lines) and DCs derived from healthy volunteers (dotted lines) was evaluated by staining with an anti-CCR1 mAb (thick lines) and isotype-matched mAb (thin lines). The results are representative of 11 experiments obtained with DCs derived from different patients as indicated in Table 1.
